Immunotherapy in atopic dermatitis.

abstract：BACKGROUND:Age-related macular degeneration (AMD) affects > 14 million individuals worldwide. Although 90% of patients with AMD have the dry form, neovascular AMD accounts for the vast majority of patients who develop legal blindness. Until recently, few treatment options existed for treatment of neovascular AMD. The a...

journal_title：Expert opinion on investigational drugs

authors： Dixon JA,Oliver SC,Olson JL,Mandava N

更新日期：2009-10-01 00:00:00

abstract：:Cyclin-dependent protein kinases (CDKs) are key regulators of the cell division cycle, whose various checkpoints proliferating cells must traverse. Since CDK deregulation, either through direct or indirect means, is found in most cancer cells, pharmacological CDK inhibition has become an attractive strategy towards me...

journal_title：Expert opinion on investigational drugs

authors： Fischer PM,Gianella-Borradori A

更新日期：2003-06-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:The evolution of targeted therapies is dependent upon identification of cellular moieties that can be pharmacologically modulated. As one such example, the serine-threonine kinase Akt was identified nearly two decades ago. Since then, its role in mediating multiple signaling cascades (ultimately...

journal_title：Expert opinion on investigational drugs

authors： Pal SK,Reckamp K,Yu H,Figlin RA

更新日期：2010-11-01 00:00:00

abstract：:Two methods of using tumour located enzymes have been described. These are antibody directed enzyme prodrug therapy (ADEPT) and macromolecule directed enzyme prodrug therapy (MDEPT), where the tumour located enzyme converts a non-toxic prodrug into a cytotoxic drug at tumour sites. The alternative use of tumour locate...

journal_title：Expert opinion on investigational drugs

authors： Bagshawe KD,Burke PJ,Knox RJ,Melton RG,Sharma SK

更新日期：1999-02-01 00:00:00

abstract：INTRODUCTION:Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN. Of these, ruxolitinib ha...

journal_title：Expert opinion on investigational drugs

authors： Tam CS,Verstovsek S

更新日期：2013-06-01 00:00:00

abstract：INTRODUCTION:Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity. Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse. Therefore, for the past few years, development of targete...

journal_title：Expert opinion on investigational drugs

authors： Vangapandu HV,Jain N,Gandhi V

更新日期：2017-05-01 00:00:00

abstract：:New bolus fibrinolytic agents derived from the recombinant human tissue plasminogen activator (t-PA) have emerged as a new means of dissolution of the occlusive thrombosis associated with acute myocardial infarction. Lanoteplase is a fibrinolytic drug derived from t-PA by deleting its fibronectin finger-like and epide...

journal_title：Expert opinion on investigational drugs

authors： Llevadot J,Guigliano RP

更新日期：2000-11-01 00:00:00

abstract：:Numerous studies over the last few years have suggested that modulating the glutamatergic system may be an efficient method to achieve an antidepressant effect. Data suggest that metabotropic glutamate receptors (mGlu receptors), related to long-term, modulatory effects on glutamatergic neurotransmission, may be a goo...

journal_title：Expert opinion on investigational drugs

authors： Palucha A

更新日期：2006-12-01 00:00:00

abstract：INTRODUCTION:Asthma is a major disease burden worldwide. Treatment with steroids and long acting β-agonists effectively manage symptoms in many patients but do not treat the underlying cause of disease and have serious side effects when used long term and in children. Therapies targeting the underlying causes of asthma...

journal_title：Expert opinion on investigational drugs

authors： Hansbro PM,Scott GV,Essilfie AT,Kim RY,Starkey MR,Nguyen DH,Allen PD,Kaiko GE,Yang M,Horvat JC,Foster PS

更新日期：2013-01-01 00:00:00

abstract：:Introduction: Cyclin-dependent kinase 7 (CDK7) is a part of the CDK-activating kinase family (CAK) which has a key role in the cell cycle and transcriptional regulation. Several lines of evidence suggest that CDK7 is a promising therapeutic target for cancer. CDK7 selective inhibitors such as SY-5609 and CT7001 are in...

journal_title：Expert opinion on investigational drugs

authors： Liang H,Du J,Elhassan RM,Hou X,Fang H

更新日期：2021-01-01 00:00:00

abstract：:A major session at this annual gathering of the cancer researchers from around the globe dealt with the current state of immunotherapy for cancer. Immunotherapy is a form of cancer treatment that enhances its scientific promise and legitimacy with each passing year. As a result, this topic has become one of the most h...

journal_title：Expert opinion on investigational drugs

authors： Salgaller ML

更新日期：2000-06-01 00:00:00

abstract：:The clinical use of cannabinoids is currently a topic of interest not exclusively, but most importantly, concerning different areas of pain therapy. One of the major obstacles in developing clinically acceptable compounds is the cannabimimetic side-effect profile of delta-9-tetrahydrocannabinol (THC) and other cannabi...

journal_title：Expert opinion on investigational drugs

authors： Karst M,Wippermann S

更新日期：2009-02-01 00:00:00

abstract：:With the current standard chemotherapy regimens only approximately 25% of acute myelogenous leukaemia (AML) patients survive > 5 years. Aurora kinases are overexpressed in many human cancers. VX-680 inhibited Aurora-A, -B, -C and the FMS-like tyrosine kinase-3 with apparent inhibitory constants of 0.6, 18, 4.6 and 30 ...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2004-09-01 00:00:00

abstract：INTRODUCTION:Relapsed/refractory multiple myeloma (rrMM) remains a difficult condition to treat despite the availability of new drugs. This review aims to provide evidence to guide physicians in the choice of salvage therapy in certain subgroups of patients. AREAS COVERED:The review attempts to present evidence-based ...

journal_title：Expert opinion on investigational drugs

authors： Offidani M,Corvatta L,Morabito F,Gentile M,Musto P,Leoni P,Palumbo A

更新日期：2011-06-01 00:00:00

abstract：:The focus of this meeting was the interface between eating disorders and obesity. A symposium at this meeting dealt with advances in treatment for bulimia nervosa (BN) and binge eating disorder. There were two presentations in this symposium that addressed pharmacological treatments. One reviewed drug treatments for B...

journal_title：Expert opinion on investigational drugs

authors： Kaplan AS

更新日期：2003-08-01 00:00:00

abstract：INTRODUCTION:AEG 35156 is an antisense oligonucleotide to X-linked inhibitor of apoptosis protein (XIAP). Overexpression of XIAP is common in acute myeloid leukemia (AML) and other cancers and is thought to cause resistance to cancer therapy. Effective treatment options for patients with relapsed or refractory AML are ...

journal_title：Expert opinion on investigational drugs

authors： Katragadda L,Carter BZ,Borthakur G

更新日期：2013-05-01 00:00:00

abstract：INTRODUCTION:Erectile function is an important aspect in the quality of life of many men. For men with erectile dysfunction (ED), a spectrum of treatment options exists. Novel therapies for ED are currently being developed in order to delay surgical placement of a penile prosthesis - the final step in the management of...

journal_title：Expert opinion on investigational drugs

authors： Smith-Harrison L,Starke NR,Smith RP,Kovac JR

更新日期：2017-06-01 00:00:00

abstract：:High-density lipoprotein (HDL) therapy is a novel and emerging area of therapeutic development in the cardiovascular field. It attempts to supplement and improve the vascular benefit exerted by other agents that are active on lipid metabolism, for example, hypolipidaemic drugs. Furthermore, it takes advantage of the n...

journal_title：Expert opinion on investigational drugs

authors： Marchesi M,Sirtori CR

更新日期：2006-03-01 00:00:00

abstract：:Diminished efficacy in terms of clinical relapses and lesion load on magnetic resonance images for patients developing neutralising antibodies (NAbs) to recombinant IFN-beta may be found in multiple sclerosis. NAbs become detectable over the first few years of therapy, disappearing during the treatment course in some ...

journal_title：Expert opinion on investigational drugs

authors： Bagnato F,Pozzilli C

更新日期：2003-07-01 00:00:00

abstract：INTRODUCTION:Aberrant regulation of platelet-derived growth factors (PDGFs) and their receptors (PDGFR) has been shown to be involved in many solid tumors, including breast cancer. PDGFR-α and PDGFR-β expressions were documented in breast cancer and are correlated with tumor aggressiveness and metastasis. Preclinical e...

journal_title：Expert opinion on investigational drugs

authors： Criscitiello C,Gelao L,Viale G,Esposito A,Curigliano G

更新日期：2014-05-01 00:00:00

abstract：INTRODUCTION:The progression of the mammalian cell cycle is driven by the transient activation of complexes consisting of cyclins and cyclin-dependent kinases (CDKs). Loss of control over the cell cycle results in accelerated cell division and malignant transformation and can be caused by the upregulation of cyclins, t...

journal_title：Expert opinion on investigational drugs

authors： Węsierska-Gądek J,Kramer MP

更新日期：2011-12-01 00:00:00

abstract：INTRODUCTION:Aurora kinases are key regulators of mitosis and inhibition of Aurora kinase activity is a rational therapeutic strategy in the treatment of solid tumors and hematological malignancies. AREAS COVERED:This paper will provide an updated summary of preclinical and clinical experience with ENMD-2076 in hemato...

journal_title：Expert opinion on investigational drugs

authors： How J,Yee K

更新日期：2012-05-01 00:00:00

abstract：:Obesity shortens life expectancy and is a risk factor for hypertension and Type 2 diabetes. When added to the standard chow of Sprague-Dawley or Otsuka Long-Evans Tokushima Fatty rats, alpha-lipoic acid (0.5% weight/weight) reduced body weight and food intake. Alpha-lipoic acid also increased whole-body energy expendi...

journal_title：Expert opinion on investigational drugs

authors： Doggrell SA

更新日期：2004-12-01 00:00:00

abstract：:The increasing frequency of fungal infections in immunocompromised patients together with the emergence of strains resistant to currently used antifungal drugs point to an increased need for a new class of antimycotics. Antimicrobial peptides are promising candidates for the treatment of fungal infections since they h...

journal_title：Expert opinion on investigational drugs

authors： Lupetti A,Danesi R,van 't Wout JW,van Dissel JT,Senesi S,Nibbering PH

更新日期：2002-02-01 00:00:00

abstract：:The vasopressin system is complex and interacts with the central nervous, cardiovascular, renal, and hematological systems. Vasopressin plays an important role in the control of blood osmolarity and vascular tone, but is also involved in many other physiological events, which are mediated mainly via three types of vas...

journal_title：Expert opinion on investigational drugs

authors： Favory R,Salgado DR,Vincent JL

更新日期：2009-08-01 00:00:00

abstract：:Aripiprazole has made a significant contribution to the treatment of schizophrenia and related disorders with an improved safety and tolerability profile, which has been attributed to its unique pharmacological profile. It has been claimed that partial agonism of the dopamine D(2) and 5-HT(1A) receptors and antagonism...

journal_title：Expert opinion on investigational drugs

authors： Wood M,Reavill C

更新日期：2007-06-01 00:00:00

abstract：UNLABELLED:IMPORTANCE OF THIS FIELD: Microtubule-inhibiting drugs are among the most commonly prescribed agents in the combat against cancer, though the clinical use of these drugs is limited by acquired resistance, risk of hypersensitivity reactions and intolerable toxicity. With progress in our understanding of cytos...

journal_title：Expert opinion on investigational drugs

authors： Chen SM,Meng LH,Ding J

更新日期：2010-03-01 00:00:00

abstract：INTRODUCTION:Despite the substantial reduction in cardiovascular morbidity and mortality after the management of dyslipidemia with statins, residual risk remains even after achieving low-density lipoprotein cholesterol targets. This residual risk appears to be partly attributed to low levels of high-density lipoprotein...

journal_title：Expert opinion on investigational drugs

authors： Milonas D,Tziomalos K

更新日期：2019-04-01 00:00:00

abstract：:Helicobacter pylori infection causes peptic ulcer disease and must be regarded as a serious infectious disease. Over the past two decades treatment of the infection has been a controversial issue. Treatment is purely empirical and based on combinations of two, three or four existing drugs. Antimicrobial resistance is ...

journal_title：Expert opinion on investigational drugs

authors： de Boer WA

更新日期：2001-08-01 00:00:00

abstract：BACKGROUND:Fenofibrate is the most widely used fibrate. Its efficacy and tolerability in the treatment of hypertriglyceridaemia and combined hyperlipidaemia have been demonstrated in several clinical trials. OBJECTIVE:To review the pharmacology, lipid-lowering and extra-lipid effects of fenofibrate and to preview ABT-...

journal_title：Expert opinion on investigational drugs

authors： Filippatos T,Milionis HJ

更新日期：2008-10-01 00:00:00